Qsymia No Product

[Anonymous]

You are an idiot, the risks of doing nothing are great when you are really obese. 10% is good, do you have something better Einstein?

Come back here when the first quarter results are in and you will realize that it will be time to get your resume back out.

 

[Anonymous]

its a date! see you in Jan

 

[Anonymous]

Did any of you see the headline today on two generics vs. this drug? Wow, good luck. There will be a lot of pressure for a short lived contract.

 

[Anonymous]

the docs will be scared of writing generics with a category X and rems - they will protect their own asses.

 

[Anonymous]

the docs will be scared of writing generics with a category X and rems - they will protect their own asses.

Drink some more Kool-Aid. Docs aren't afraid of writing generics, escpecially when they are proven to work as effective as a drug not covered by insurance....and patients are going to pay cash when they can get it generic. Not to mention pharmacist will try to switch to generic so they will make more money on the scripts. No brainer!

 

[Anonymous]

Thathas to sting just a little....

VIVUS tumbles after firm says doctors may replace company's drug with generics
Anti-obesity drug maker VIVUS (VVUS) is sinking after research firm Jefferies downgraded the stock to Underperform from Hold based on its belief that doctors may prescribe two generic drugs instead of VIVUS's product. in a note to investors earlier today, Jefferies stated that VIVUS's anti-obesity drug, Qsymia, is a combination of two generic drugs, topiramate and phentermine. Since insurers are unlikely to cover Qsymia, doctors will have a strong incentive to prescribe the two generic drugs instead, the firm argues. While VIVUS contends that doctors will be reluctant to prescribe the generic pills for an off-label use, i.e. obesity treatment, due to liability concerns, Jefferies, after studying the matter, said it's "increasingly skeptical" about this argument. Finally, the firm, noting that VIVUS itself used the two generic pills during a proof of concept study, says data suggests that there's no material difference between the effectiveness of VIVUS' Qsymia and the two generic drugs. Jefferies reduced its estimate for peak Qsymia sales to $1.2B from $3.6B and slashed its target on the shares to $16 from $31. In early trading, VIVUS tumbled $1.51, or 6.63%, to $21.25.